Table TDI-12. Characteristics of all women treated for drug problems in 2002 or most recent year available. Part (ii) Distribution of primary drug (percentage)
| Country | Opiates | Cocaine | Amphetamines | Ecstasy | Hallucinogens | Cannabis | Others | ||||
| Belgium | (1) | 61 | 2 | 5 | 2 | 0 | 15 | 15 | |||
| Czech Republic | (2) | 25.6 | 0.1 | 53.3 | 2.6 | 0.2 | 13.8 | 4.4 | |||
| Denmark | (3) | 46 | 2 | 5 | 2 | 0 | 23 | 22 | |||
| Germany | (4) | 54 | 4 | 9 | na | 0 | 22 | 11 | |||
| Greece | 88.5 | 2.5 | 0 | 0.8 | 0 | 5.5 | 2.7 | ||||
| Spain | (17) | 64 | 22 | 1 | 1 | 0 | 7 | 5 | |||
| France | (5) | 78.6 | 4 | 0.5 | 0.4 | 0.2 | 10.1 | 6.2 | |||
| Ireland | (6) | 77.2 | 0.6 | 0.4 | 4.6 | 0.1 | 13.1 | 4 | |||
| Italy | (7) | na | na | na | na | na | na | na | |||
| Latvia | (8) | 80.2 | 0 | 10.7 | na | 0.2 | 0.2 | 8.7 | |||
| Lithuania | (9) | na | na | na | na | na | na | na | |||
| Luxembourg | 79 | 9 | 0 | 0 | 0 | 8 | 4 | ||||
| Hungary | (11) | na | na | na | na | na | na | na | |||
| Netherlands | (12) | 40 | 32 | 3 | 1 | 0 | 17 | 7 | |||
| Austria | (13) | 100 | |||||||||
| Slovenia | 86 | 1.2 | 0.2 | 0.7 | 0 | 10.5 | 1.4 | ||||
| Slovakia | 78.9 | 0.2 | 5.4 | 0.2 | 0 | 5.8 | 9.5 | ||||
| Finland | 33.2 | 0 | 39.9 | 0.9 | 0 | 15.8 | 10.2 | ||||
| Sweden | (15) | 28 | 1 | 29 | 1 | 0 | 18 | 23 | |||
| United Kingdom | (16) | 77 | 6 | 4 | 1 | 0 | 7 | 5 | |||
| Notes: | |||||||||||
| Data were not available for: Estonia, Cyprus, Malta, Poland and Norway. | |||||||||||
| Injecting as a route of administration is not reported for cannabis. | |||||||||||
| Belgium | (1) | Data refer only to outpatient treatment centres. Last data available refer to 1999 | |||||||||
| Czech Republic | (2) | Data refer to all treatment centres. | |||||||||
| Denmark | (3) | Injecting use for opiates refers only to heroin, and cocaine only to cocaine CIH. For distribution by main drug only clients attending outpatient centres. | |||||||||
| Germany | (4) | Data only refer to outpatient treatment centres; information about injecting use is not available. Amphetamines also include ecstasy. | |||||||||
| France | (5) | The last available data on treatment demand are reported, referring to the annual census on clients in treatment carried out in November 1999. | |||||||||
| Ireland | (6) | Last data available refer to 2000. | |||||||||
| Italy | (7) | Data only refer to outpatient treatment centres; information about injecting opiate use refers only to heroin, for cocaine only to cocaine CIH. | |||||||||
| Latvia | (8) | Data refer only to outpatient treatment centres. | |||||||||
| Lithuania | (9) | Amphetamines include all stimulants. | |||||||||
| Hungary | (11) | 39% of clients are reported to use hypnotics/sedatives, 18% other substances. | |||||||||
| Netherlands | (12) | Data refer only to outpatient treatment centres. | |||||||||
| Austria | (13) | Data refer to clients in substitution treatment only; figures for opiates as main drug and injecting use are consequently 100%. | |||||||||
| Portugal | (14) | Coverage is limited and variable, with no control on double counting of clients. | |||||||||
| Sweden | (15) | Data refer only to outpatient treatment centres. | |||||||||
| United Kingdom | (16) | Data relate to the period from 1 April 2001 to 31 March 2002 for Scotland and Northern Ireland; for England and Wales six months data ending 30 September 2000 plus six months data ending 31 March 2001. | |||||||||
| Spain | (17) | Data on men and women only concern outpatient treatment centres. | |||||||||
| Sources: 2003 Reitox national reports, Standard table, 3 see [Table TDI-10 Part (iii)] for details on sources. | |||||||||||
